Treatment

CAR T-Cell Therapy Offers Hope for Relapsed Multiple Myeloma

Multiple myeloma (MM) impacts around 35,000 new patients annually in the United States, with over 12,000 deaths. Advances in treatments like proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies...

CURATED BY: Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Laura J. Zitella

MS, RN, ACNP-BC, AOCN
Nurse Practitioner, Associate Clinical Professor, University of California San Francisco

Rare Multiple Myeloma Case in Pregnancy Successfully Managed With Treatment, Leading to Healthy Delivery

Multiple myeloma (MM) during pregnancy is rare, with only 45 cases reported between 1965 and 2020. In the presented case, a 40-year-old woman was diagnosed with oligosecretory IgG kappa MM...

CURATED BY:
Jill N. Burke,
CNP, DipACLM

Managing Multiple Myeloma: Addressing Bone Disease and Improving Treatment Options for Older Adults

Multiple myeloma (MM) is a cancer of clonal plasma cells primarily affecting older adults, with approximately 35,000 new cases annually in the United States. Advances in treatment, including immunomodulatory drugs,...

CURATED BY:
Jill N. Burke,
CNP, DipACLM

Tailoring CAR-T Therapy for Older Adults: Addressing Frailty and Improving Outcomes

CAR-T therapy has been effective in treating relapsed/refractory hematologic cancers like multiple myeloma and diffuse large B-cell lymphoma, especially in older adults. However, its use in patients aged 75 and...

CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Efficacy of Daratumumab Regimens in Transplant-Eligible Patients With NDMM With High-Risk Cytogenetic Abnormalities

The MASTER study (NCT03224507) and GRIFFIN study (NCT02874742) evaluated the efficacy of daratumumab-containing regimens in transplant-eligible newly diagnosed patients with multiple myeloma (NDMM) with high-risk cytogenetic abnormalities (HRCAs)....

CURATED BY:
Danielle Roberts,
MS, MMSc, PA-C

Study Unveils Key Predictors of Success in BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma

B-cell maturation antigen (BCMA) -targeting CAR T cells have revolutionized the treatment of relapsed/refractory multiple myeloma....

CURATED BY:
Jill N. Burke,
CNP, DipACLM

Advanced BCMA-Targeted Therapies Promise New Hope for Incurable Multiple Myeloma

Despite significant advancements in multiple myeloma (MM) treatment, MM remains largely incurable, particularly for relapsed or refractory cases. The focus on B-cell maturation antigen (BCMA) as a target has shifted...

CURATED BY:
Jill N. Burke,
CNP, DipACLM

Company
Contact

Partner with Us
Ambassador Program

Treatment

CAR T-Cell Therapy Offers Hope for Relapsed Multiple Myeloma

Laura J. Zitella

Rare Multiple Myeloma Case in Pregnancy Successfully Managed With Treatment, Leading to Healthy Delivery

Managing Multiple Myeloma: Addressing Bone Disease and Improving Treatment Options for Older Adults

Tailoring CAR-T Therapy for Older Adults: Addressing Frailty and Improving Outcomes

Efficacy of Daratumumab Regimens in Transplant-Eligible Patients With NDMM With High-Risk Cytogenetic Abnormalities

Study Unveils Key Predictors of Success in BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Advanced BCMA-Targeted Therapies Promise New Hope for Incurable Multiple Myeloma

© 2024 Point of Care Network, LLC. All Rights Reserved.

© 2024 Point of Care Network, LLC. All Rights Reserved.

Share